ITT (ITT)
(Delayed Data from NYSE)
$130.48 USD
+0.94 (0.73%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $130.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
ITT 130.48 +0.94(0.73%)
Will ITT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ITT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITT
Honeywell (HON) to Report Q1 Earnings: Is a Beat in Store?
GE Aerospace (GE) Gears Up for Q1 Earnings: What to Expect
ITT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Honeywell (HON) in Your Portfolio
3 Reasons Why Growth Investors Shouldn't Overlook ITT (ITT)
Here's Why ITT (ITT) is a Strong Momentum Stock
Other News for ITT
Merck garners Canadian approval for Keytruda in first-line gastroesophageal cancer
Beyond The Numbers: 4 Analysts Discuss ITT Stock
ITT price target raised by $9 at Stifel, here's why
ITT Announces Participation in Oppenheimer’s 19th Annual Industrial Growth Conference
Viracta Therapeutics reports positive results from stage 1 of phase 2 trial for lymphoma treatment